

DAFTAR PUSTAKA

- Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R. and Ebi, H., 2020. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. *Clinical Cancer Research*, 26 (22), 5962–5973.
- Adamczyk, A., Grela-Wojewoda, A., Domagała-Haduch, M., Ambicka, A., Harazin-Lechowska, A., Janecka, A., Cedrych, I., Majchrzyk, K., Kruczak, A., Ryś, J. and Niemiec, J., 2017. Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting. *Journal of Cancer*, 8 (1), 131–139.
- Adan, A., Kiraz, Y. and Baran, Y., 2016. Cell Proliferation and Cytotoxicity Assays. *Current Pharmaceutical Biotechnology*, 17 (14), 1213–1221.
- Amberger, J. S., Bocchini, C. A., Scott, A. F. and Hamosh, A., 2019. OMIM.org: leveraging knowledge across phenotype–gene relationships. *Nucleic Acids Research*, 47 (D1), D1038–D1043.
- Bahl, A., Singh, R., Wadhwa, J., Gupta, S., Ahmed, M., Uppal, P. N., Parikh, P. M. and Aggarwal, S., 2018. Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer. *South Asian Journal of Cancer*, 07 (02), 102–105.
- Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., Yefanov, A., Lee, H., Zhang, N., Robertson, C. L., Serova, N., Davis, S. and Soboleva, A., 2012. NCBI GEO: archive for functional genomics data sets—update. *Nucleic Acids Research*, 41 (D1), D991–D995.
- Behera, S., Yadav, T., Singh, S. P. and Thatoi, H., 2023. *Genome Data Resources and Tools for Sequence Analysis*. Advances in Bioinformatics and Big Data Analytics.
- Bie, B., Sun, J., Guo, Y., Li, J., Jiang, W., Yang, J., Huang, C. and Li, Z., 2017. Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma. *Biomedicine & Pharmacotherapy*, 93, 1285–1291.
- Brady, S. W., Zhang, J., Tsai, M.-H. and Yu, D., 2015a. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. *Cancer Biology and Therapy*, 16 (3), 402–411.
- Brady, S. W., Zhang, J., Tsai, M.-H. and Yu, D., 2015b. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. *Cancer Biology and Therapy*, 16 (3), 402–411.
- Burstein, H. J., Storniolo, A. M., Franco, S., Forster, J., Stein, S., Rubin, S., Salazar, V. M. and Blackwell, K. L., 2008. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. *Annals of Oncology*, 19 (6), 1068–1074.
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., Antipin, Y., Reva, B.,

- Goldberg, A. P., Sander, C. and Schultz, N., 2012. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. *Cancer Discovery*, 2 (5), 401–404.
- Chen, S., Liu, C.-L., Zhao, Q., Sun, H.-P. and Liu, Y.-X., 2020. Identification of hub genes and key pathways in breast cancer by survival-based bioinformatics analysis. *Journal of Shanghai Jiaotong University (Medical Science)*, 40 (3), 294–302.
- Chen, T., Zhang, P., Cong, X.-F., Wang, Y.-Y., Li, S., Wang, H., Zhao, S.-R. and Sun, X.-J., 2024. Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway. *Frontiers in Pharmacology*, 15.
- Chen, Y., Wang, J., Hong, D.-Y., Chen, L., Zhang, Y.-Y., Xu, Y.-N., Pan, D., Fu, L.-Y., Tao, L., Luo, H., Luo, H. and Shen, X.-C., 2017. Baicalein has protective effects on the 17 β -estradiol-induced transformation of breast epithelial cells. *Oncotarget*, 8 (6), 10470–10484.
- Chicco, D. and Jurman, G., 2022. A brief survey of tools for genomic regions enrichment analysis. *Frontiers in Bioinformatics*, 2.
- Chin, C.-H., Chen, S.-H., Wu, H.-H., Ho, C.-W., Ko, M.-T. and Lin, C.-Y., 2014a. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Systems Biology*, 8 (S4), S11.
- Chin, C.-H., Chen, S.-H., Wu, H.-H., Ho, C.-W., Ko, M.-T. and Lin, C.-Y., 2014b. cytoHubba: Identifying hub objects and sub-networks from complex interactome. *BMC Systems Biology*, 8 (4).
- Chuang, T., Fang, G., Hsu, S., Lee, Y., Shao, W., Wang, V., Lee, S., Kao, M. and Ou, C., 2023a. Baicalein suppresses HER2-mediated malignant transformation of HER2-overexpressing ovarian cancer cells by downregulating HER2 gene expression. *Environmental Toxicology*, 38 (7), 1609–1617.
- Chuang, T.-C., Fang, G.-S., Hsu, S.-C., Lee, Y.-J., Shao, W.-S., Wang, V., Lee, S.-L., Kao, M.-C. and Ou, C.-C., 2023b. Baicalein suppresses HER2-mediated malignant transformation of HER2-overexpressing ovarian cancer cells by downregulating HER2 gene expression. *Environmental Toxicology*, 38 (7), 1609–1617.
- Clough, E., Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Kochergin, A. and Soboleva, A., 2024. NCBI GEO: archive for gene expression and epigenomics data sets: 23-year update. *Nucleic Acids Research*, 52 (D1), D138–D144.
- Daina, A., Michielin, O. and Zoete, V., 2019. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Research*, 47 (W1), W357–W364.
- D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R. and Bianco, R., 2015. Mechanisms of lapatinib resistance in HER2-driven breast cancer. *Cancer Treatment Reviews*, 41 (10), 877–883.

- Degirmenci, U., Wang, M. and Hu, J., 2020. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. *Cells*, 9 (1).
- Deng, J.-L., Xu, Y. and Wang, G., 2019. Identification of Potential Crucial Genes and Key Pathways in Breast Cancer Using Bioinformatic Analysis. *Frontiers in Genetics*, 10.
- Doncheva, N. T., Morris, J. H., Gorodkin, J. and Jensen, L. J., 2019. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. *Journal of Proteome Research*, 18 (2), 623–632.
- Elizarraras, J. M., Liao, Y., Shi, Z., Zhu, Q., Pico, A. R. and Zhang, B., 2024. WebGestalt 2024: Faster gene set analysis and new support for metabolomics and multi-omics. *Nucleic Acids Research*, 52 (W1), W415–W421.
- Eustace, A. J., Conlon, N. T., McDermott, M. S. J., Browne, B. C., O’Leary, P., Holmes, F. A., Espina, V., Liotta, L. A., O’Shaughnessy, J., Gallagher, C., O’Driscoll, L., Rani, S., Madden, S. F., O’Brien, N. A., Ginther, C., Slamon, D., Walsh, N., Gallagher, W. M., Zagazdzon, R., Watson, W. R., O’Donovan, N. and Crown, J., 2018a. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. *BMC Cancer*, 18 (1), 965.
- Eustace, A. J., Conlon, N. T., McDermott, M. S. J., Browne, B. C., O’Leary, P., Holmes, F. A., Espina, V., Liotta, L. A., O’Shaughnessy, J., Gallagher, C., O’Driscoll, L., Rani, S., Madden, S. F., O’Brien, N. A., Ginther, C., Slamon, D., Walsh, N., Gallagher, W. M., Zagazdzon, R., Watson, W. R., O’Donovan, N. and Crown, J., 2018b. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. *BMC Cancer*, 18 (1), 965.
- Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I. and Bray, F., 2024. *Global Cancer Observatory: Cancer Today* [online]. International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today> [Accessed 18 Aug 2024].
- Galogre, M., Rodin, D., Pyatnitskiy, M., Mackelprang, M. and Koman, I., 2023. A review of HER2 overexpression and somatic mutations in cancers. *Critical Reviews in Oncology/Hematology*, 186, 103997.
- Ganot, N., Meker, S., Reytman, L., Tzuber, A. and Tshuva, E. Y., 2013. Anticancer metal complexes: synthesis and cytotoxicity evaluation by the MTT assay. *Journal of visualized experiments : JoVE*, (81).
- Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Sander, C. and Schultz, N., 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Science Signaling*, 6 (269).
- Gao, X.-Y., Xue, X.-H., Ma, Y.-N. and Zhang, S.-Q., 2015. Effect of baicalein on the expression of SATB1 in human breast cancer cells. *Experimental and Therapeutic Medicine*, 9 (5), 1665–1669.
- Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., Davies, M., Dedman, N., Karlsson, A., Magariños, M. P., Overington, J. P., Papadatos, G.,

- Smit, I. and Leach, A. R., 2017. The ChEMBL database in 2017. *Nucleic Acids Research*, 45 (D1), D945–D954.
- Gayle, S. S., Arnold, S. L. M., O'Regan, R. M. and Nahta, R., 2012. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. *Anti-Cancer Agents in Medicinal Chemistry*, 12 (2), 151–162.
- Gollamudi, J., Parvani, J. G., Schiemann, W. P. and Vinayak, S., 2016. Neoadjuvant therapy for early-stage breast cancer: The clinical utility of pertuzumab. *Cancer Management and Research*, 8, 21–31.
- Gu, L., Xu, F., Zhang, X. and Gu, Z., 2022. Baicalein Inhibits the SMYD2/RPS7 Signaling Pathway to Inhibit the Occurrence and Metastasis of Lung Cancer. *Journal of Oncology*, 2022.
- Gu, S. and Lai, L., 2020. Associating 197 Chinese herbal medicine with drug targets and diseases using the similarity ensemble approach. *Acta Pharmacologica Sinica*, 41 (3), 432–438.
- Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P. and Minghim, R., 2015. InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. *BMC Bioinformatics*, 16 (1), 169.
- Hermawan, A., Putri, H. and Utomo, R. Y., 2020. Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance. *Molecular Diversity*, 24 (4), 933–947.
- Hermawan, A., Windarsih, A., Putri, D. D. P. and Fatimah, N., 2025. LC-HRMS-based global metabolomics profiling unravels the distinct metabolic signature of lapatinib-resistant and trastuzumab-resistant HER2+ breast cancer cells. *Journal of Pharmaceutical and Biomedical Analysis*, 253.
- Hermawan, A., Wulandari, F., Hanif, N., Utomo, R. Y., Jenie, R. I., Ikawati, M. and Tafrihani, A. S., 2022. Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment: integrated computational analysis and in vitro study. *Scientific Reports*, 12 (1), 13928.
- Hu, D., Lin, Z., Jiang, J., Li, P., Zhang, Z. and Yang, C., 2022. Identification of Key Genes and Molecular Pathways in Keratoconus: Integrating Text Mining and Bioinformatics Analysis. *BioMed Research International*, 2022.
- Huang, D. W., Sherman, B. T. and Lempicki, R. A., 2009a. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature Protocols*, 4 (1), 44–57.
- Huang, D. W., Sherman, B. T. and Lempicki, R. A., 2009b. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nature Protocols*, 4 (1), 44–57.
- Huang, D. W., Sherman, B. T., Zheng, X., Yang, J., Imamichi, T., Stephens, R. and Lempicki, R. A., 2009. Extracting biological meaning from large gene lists with DAVID. *Current Protocols in Bioinformatics*, (SUPPL. 27).
- Huang, W.-C., Hung, C.-M., Wei, C.-T., Chen, T.-M., Chien, P.-H., Pan, H.-L., Lin, Y.-M. and Chen, Y.-J., 2016. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells. *Oncotarget*, 7 (38), 62352–62363.

- Hussain, I., Waheed, S., Ahmad, K. A., Pirog, J. E. and Syed, V., 2018. Scutellaria baicalensis targets the hypoxia-inducible factor-1 α and enhances cisplatin efficacy in ovarian cancer. *Journal of Cellular Biochemistry*, 119 (9), 7515–7524.
- Ignatchenko, V., Ignatchenko, A., Sinha, A., Boutros, P. C. and Kislinger, T., 2015. VennDIS: A JavaFX-based Venn and Euler diagram software to generate publication quality figures. *Proteomics*, 15 (7), 1239–1244.
- Iwata, H., Fujii, H., Masuda, N., Mukai, H., Nishimura, Y., Katsura, K., Ellis, C. E., Gagnon, R. C. and Nakamura, S., 2015. Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study. *Breast Cancer*, 22 (2), 192–200.
- Karakashev, S. V. and Reginato, M. J., 2015. Hypoxia/HIF1 induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. *Oncotarget*, 6 (4), 1967–1980.
- Katara, P., 2014. Potential of Bioinformatics as functional genomics tool: An overview. *Network Modeling and Analysis in Health Informatics and Bioinformatics*, 3 (1), 1–7.
- Kavarthapu, R., Anbazhagan, R., Sharma, A. K., Shiloach, J. and Dufau, M. L., 2020. Linking Phospho-Gonadotropin Regulated Testicular RNA Helicase (GRTH/DDX25) to Histone Ubiquitination and Acetylation Essential for Spermatid Development During Spermiogenesis. *Frontiers in Cell and Developmental Biology*, 8.
- Kay, C., Martínez-Pérez, C., Meehan, J., Gray, M., Webber, V., Dixon, J. M. and Turnbull, A. K., 2021. Current Trends in the Treatment of HR+/HER2+ Breast Cancer. *Future Oncology*, 17 (13), 1665–1681.
- Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., Wang, J., Yu, B., Zhang, J. and Bryant, S. H., 2016. PubChem Substance and Compound databases. *Nucleic Acids Research*, 44 (D1), D1202–D1213.
- Kuchukulla, R. R., Hwang, I., Park, S. W., Moon, S., Kim, S. H., Kim, S., Chung, H. W., Ji, M.-J., Park, H.-M., Kong, G., Kong, G. and Hur, W., 2022. Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers. *Pharmaceuticals*, 15 (9).
- Kumar, R., Gupta, M. and Sarwat, M., 2022. Bioinformatics in Drug Design and Delivery. In: *Computer Aided Pharmaceutics and Drug Delivery*. Singapore: Springer Nature Singapore, 641–664.
- Kumari, N., Dwarakanath, B. S., Das, A. and Bhatt, A. N., 2016. Role of interleukin-6 in cancer progression and therapeutic resistance. *Tumor Biology* [online], 37 (9), 11553–11572. Available from: <https://doi.org/10.1007/s13277-016-5098-7>.
- Di Leo, A., Gomez, H. L., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrero, S. F., Koehler, M., Oliva, C., Stein, S. H., Finn, R. S. and Press, M. F., 2008. Phase III, double-blind, randomized study comparing lapatinib plus

- paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. *Journal of Clinical Oncology*, 26 (34), 5544–5552.
- Li, J., Duan, B., Guo, Y., Zhou, R., Sun, J., Bie, B., Yang, S., Huang, C., Yang, J. and Li, Z., 2018. Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. *Biomedicine & Pharmacotherapy*, 98, 806–812.
- LIANG, R.-R., ZHANG, S., QI, J.-A., WANG, Z.-D., LI, J., LIU, P.-J., HUANG, C., LE, X.-F., YANG, J. and LI, Z.-F., 2012. Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. *International Journal of Oncology*, 41 (3), 969–978.
- Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. and Zhang, B., 2019. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Research*, 47 (W1), W199–W205.
- Lin, H., Hao, Y., Wan, X., He, J. and Tong, Y., 2020. Baicalein inhibits cell development, metastasis and EMT and induces apoptosis by regulating ERK signaling pathway in osteosarcoma. *Journal of Receptors and Signal Transduction*, 40 (1), 49–57.
- Liu, C., Wu, S., Hou, L., Wang, X., Wang, L. and Shi, Y., 2014. Study on cytotoxicity tests of medical devices based on IC50. *Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation*, 38 (6).
- Liu, S., Ma, Z., Cai, H., Li, Q., Rong, W. and Kawano, M., 2010. Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells. *European Journal of Haematology*, 84 (2), 137–144.
- Liu, Y.-N., Wan, R.-Z. and Liu, Z.-P., 2013. Recent developments of small molecule PI3K/mTOR dual inhibitors. *Mini-Reviews in Medicinal Chemistry*, 13 (14), 2047–2059.
- Liu, Z.-H., Yang, C.-X., Zhang, L., Yang, C.-Y. and Xu, X.-Q., 2019. Baicalein, as a prooxidant, triggers mitochondrial apoptosis in MCF-7 human breast cancer cells through mobilization of intracellular copper and reactive oxygen species generation. *OncoTargets and Therapy*, 12, 10749–10761.
- Loibl, S. and Gianni, L., 2017. HER2-positive breast cancer. *The Lancet*, 389 (10087), 2415–2429.
- Lu, W. and Kang, Y., 2019. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. *Developmental Cell*, 49 (3), 361–374.
- De Luca, A., D'Alessio, A., Gallo, M., Maiello, M. R., Bode, A. M. and Normanno, N., 2014. Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. *Cell Cycle*, 13 (1), 148–156.
- Lund, O., Laugesen, J. L. and Mosekilde, E., 2012. *Concepts in mechanism based modeling*. Biosimulation in Biomedical Research, Health Care and Drug Development.
- Ma, X.-C., Yan, W., Dai, Z., Gao, X., Ma, Y., Xu, Q., Jiang, J. and Zhang, S., 2016. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/ β -catenin pathway. *Drug Design, Development and Therapy*, 1419.
- Ma, Z., Otsuyama, K., Liu, S., Abroun, S., Ishikawa, H., Tsuyama, N., Obata, M., Li, F.-J., Zheng, X., Maki, Y., Miyamoto, K. and Kawano, M. M., 2005.

- Baicalein, a component of *Scutellaria radix* from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. *Blood*, 105 (8), 3312–3318.
- Ma'ayan, A. and Iyengar, R., 2006. From components to regulatory motifs in signalling networks. *Briefings in Functional Genomics and Proteomics*, 5 (1), 57–61.
- Masseroli, M., 2018. *Biological and medical ontologies: GO and GOA*. Encyclopedia of Bioinformatics and Computational Biology: ABC of Bioinformatics.
- Moreira, C. and Kaklamani, V., 2010. Lapatinib and breast cancer: Current indications and outlook for the future. *Expert Review of Anticancer Therapy*, 10 (8), 1171–1182.
- National Center for Biotechnology Information, 2025, PubChem Compound Summary for CID 5281605, Baicalein, <https://pubchem.ncbi.nlm.nih.gov/compound/Baicalein>, March 10, 2025.
- National Center for Biotechnology Information, 2025, PubChem Compound Summary for CID 208908, Lapatinib, <https://pubchem.ncbi.nlm.nih.gov/compound/Lapatinib>, March 10, 2025.
- Nopi, N. S. and Isnaeni, N., 2024. Validasi Metode Analisis Penetapan Kadar Bahan Baku Lapatinib Ditosylate secara KCKT-DAD. *Eruditio : Indonesia Journal of Food and Drug Safety*, 4 (1), 33–42.
- Park, C. H., Han, S. E., Nam-Goong, I. S., Kim, Y. Il and Kim, E. S., 2018. Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways. *Endocrinology and Metabolism*, 33 (1), 121.
- Peiró, G., Ortiz-Martínez, F., Gallardo, A., Pérez-Balaguer, A., Sánchez-Payá, J., Ponce, J. J., Tibau, A., López-Vilaro, L., Escuin, D., Adrover, E., Barnadas, A. and Lerma, E., 2014. Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. *British Journal of Cancer*, 111 (4), 689–695.
- Putra, I. M. R., Lestari, I. A., Fatimah, N., Hanif, N., Ujiantari, N. S. O., Putri, D. D. P. and Hermawan, A., 2024. Bioinformatics and In Vitro Study Reveal ERα as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells. *Computational Biology and Chemistry*, 111, 108084.
- Qiao, D., Li, Y., Xing, J., Sun, P., Wang, Y., Zhang, Y., Chen, L., Ren, X., Lin, Z., Jin, J. and Piao, Y., 2019. [Baicalein inhibits PI3K/AKT signaling pathway and induces autophagy of MGC-803 cells]. *Xi bao yu fen zi mian yi xue za zhi* = *Chinese journal of cellular and molecular immunology*, 35 (7), 613–618.
- Qiao, D., Xing, J., Duan, Y., Wang, S., Yao, G., Zhang, S., Jin, J., Lin, Z., Chen, L. and Piao, Y., 2022. The molecular mechanism of baicalein repressing progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway. *Phytomedicine*, 100.
- Riss, T. L., Moravec, R. A. and Niles, A. L., 2013. *Cell Viability Assays*.

- Rogers, D. M. and Rempe, S. B., 2011. Probing the thermodynamics of competitive ion binding using minimum energy structures. *Journal of Physical Chemistry B*, 115 (29), 9116–9129.
- Salminen, A. and Kaarniranta, K., 2010. Insulin/IGF-1 paradox of aging: Regulation via AKT/IKK/NF- κ B signaling. *Cellular Signalling*, 22 (4), 573–577.
- Shang, D., Li, Z., Zhu, Z., Chen, H., Zhao, L., Wang, X. and Chen, Y., 2015. Baicalein suppresses 17- β -estradiol-induced migration, adhesion and invasion of breast cancer cells via the G protein-coupled receptor 30 signaling pathway. *Oncology Reports*, 33 (4), 2077–2085.
- Sherman, B. T., Hao, M., Qiu, J., Jiao, X., Baseler, M. W., Lane, H. C., Imamichi, T. and Chang, W., 2022. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucleic Acids Research*, 50 (W1), W216–W221.
- Soltantoyeh, T., Bahadori, T., Hosseini-Ghatar, R., Khoshnoodi, J., Roohi, A., Mobini, M., Golsaz-Shirazi, F., Jeddi-Tehrani, M., Amiri, M. M. and Shokri, F., 2018. Differential effects of inhibitory and stimulatory anti-HER2 monoclonal antibodies on AKT/ERK signaling pathways. *Asian Pacific Journal of Cancer Prevention*, 19 (8), 2255–2262.
- Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., Stein, T. I., Nudel, R., Lieder, I., Mazor, Y., Kaplan, S., Dahary, D., Warshawsky, D., Guan-Golan, Y., Kohn, A., Rappaport, N., Safran, M. and Lancet, D., 2016. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Current Protocols in Bioinformatics*, 54 (1).
- Su, G., Morris, J. H., Demchak, B. and Bader, G. D., 2014. Biological Network Exploration with Cytoscape 3. *Current Protocols in Bioinformatics*, 2014, 8.13.1-8.13.24.
- Sudakov, K. V., 2011. [From molecules and genes to functional systems]. *Patologicheskaya fiziologiya i eksperimental'naya terapiya*, (4), 3–6.
- Sylvester, P. W., 2011. *Optimization of the Tetrazolium Dye (MTT) Colorimetric Assay for Cellular Growth and Viability*. Methods in Molecular Biology.
- Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J. and Mering, C. von, 2019. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research*, 47 (D1), D607–D613.
- Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J. and Von Mering, C., 2019. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Research*, 47 (D1), D607–D613.
- Tang, D., Zhao, X., Zhang, L., Wang, Z. and Wang, C., 2019. Identification of hub genes to regulate breast cancer metastasis to brain by bioinformatics analyses. *Journal of Cellular Biochemistry*, 120 (6), 9522–9531.
- Tang, Z., Phan, S., Pan, Y. and Famili, A. F., 2007. Prediction of co-regulated gene groups through gene ontology. In: *2007 IEEE Symposium on Computational*

- Intelligence and Bioinformatics and Computational Biology, CIBCB 2007*. 178–184.
- Tanizaki, J., Okamoto, I., Fumita, S., Okamoto, W., Nishio, K. and Nakagawa, K., 2011. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. *Oncogene*, 30 (39), 4097–4106.
- Tian, J., Li, J., Bie, B., Sun, J., Mu, Y., Shi, M., Zhang, S., Kong, G., Li, Z. and Guo, Y., 2021. MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF- κ B signaling. *Toxicology and Applied Pharmacology*, 420.
- Wang, M., Qiu, S. and Qin, J., 2019. Baicalein induced apoptosis and autophagy of undifferentiated thyroid cancer cells by the ERK/PI3K/AKT pathway. *American Journal of Translational Research*, 11 (6), 3341–3352.
- Wang, Q., Quan, H., Zhao, J., Xie, C., Wang, L. and Lou, L., 2013a. RON confers lapatinib resistance in HER2-positive breast cancer cells. *Cancer Letters*, 340 (1), 43–50.
- Wang, Q., Quan, H., Zhao, J., Xie, C., Wang, L. and Lou, L., 2013b. RON confers lapatinib resistance in HER2-positive breast cancer cells. *Cancer Letters*, 340 (1), 43–50.
- Wang, Q., Quan, H., Zhao, J., Xie, C., Wang, L. and Lou, L., 2013c. RON confers lapatinib resistance in HER2-positive breast cancer cells. *Cancer Letters*, 340 (1), 43–50.
- Wang, T. and Tang, H., 2017. The physical characteristics of human proteins in different biological functions. *PLoS ONE*, 12 (5).
- Wang, Y.-C., Morrison, G., Gillihan, R., Guo, J., Ward, R. M., Fu, X., Botero, M. F., Healy, N. A., Hilsenbeck, S. G., Phillips, G. L., Chamness, G. C., Rimawi, M. F., Osborne, C. K. and Schiff, R., 2011. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation. *Breast Cancer Research*, 13 (6), R121.
- Wang, Z., Liao, X., He, H., Guo, X. and Chen, J., 2024. Targeting the STAT3 pathway with STAT3 degraders. *Trends in Pharmacological Sciences*, 45 (9), 811–823.
- Winkler, F. K., 2006. Amt/MEP/Rh proteins conduct ammonia. *Pflügers Archiv European Journal of Physiology*, 451 (6), 701–707.
- Xia, W., Petricoin III, E. F., Zhao, S., Liu, L., Osada, T., Cheng, Q., Wulfkühle, J. D., Gwin, W. R., Yang, X., Gallagher, R. I., Lyerly, H. K. and Spector, N. L., 2013a. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. *Breast Cancer Research*, 15 (5).
- Xia, W., Petricoin III, E. F., Zhao, S., Liu, L., Osada, T., Cheng, Q., Wulfkühle, J. D., Gwin, W. R., Yang, X., Gallagher, R. I., Lyerly, H. K. and Spector, N. L., 2013b. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. *Breast Cancer Research*, 15 (5).

- Xia, X., 2017a. Bioinformatics and Drug Discovery. *Current Topics in Medicinal Chemistry*, 17 (15), 1709–1726.
- Xia, X., 2017b. Bioinformatics and Drug Discovery. *Current Topics in Medicinal Chemistry*, 17 (15), 1709–1726.
- Xu, Z.-Q., Zhang, Y., Li, N., Liu, P.-J., Gao, L., Gao, X. and Tie, X.-J., 2017. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: A systematic review and meta-analysis of randomised controlled trials. *BMJ Open*, 7 (3).
- Yan, W., Ma, X., Zhao, X. and Zhang, S., 2018a. Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro. *Drug Design, Development and Therapy*, Volume 12, 3961–3972.
- Yan, W., Ma, X., Zhao, X. and Zhang, S., 2018b. Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro. *Drug Design, Development and Therapy*, 12, 3961–3972.
- Yan, W., Ma, X., Zhao, X. and Zhang, S., 2018c. Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro. *Drug Design, Development and Therapy*, 12, 3961–3972.
- Yao, Z.-J., Dong, J., Che, Y.-J., Zhu, M.-F., Wen, M., Wang, N.-N., Wang, S., Lu, A.-P. and Cao, D.-S., 2016. TargetNet: a web service for predicting potential drug–target interaction profiling via multi-target SAR models. *Journal of Computer-Aided Molecular Design*, 30 (5), 413–424.
- Zervantonakis, I. K., Poskus, M. D., Scott, A. L., Selfors, L. M., Lin, J.-R., Dillon, D. A., Pathania, S., Sorger, P. K., Mills, G. B. and Brugge, J. S., 2020. Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. *Proceedings of the National Academy of Sciences of the United States of America*, 117 (28), 16500–16508.
- Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., Rao, Y. and Chen, C., 2024. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. *Cancer Letters*, 598.
- Zhao, X., Qu, J., Liu, X., Wang, J., Ma, X., Zhao, X., Yang, Q., Yan, W., Zhao, Z., Hui, Y., Bai, H. and Zhang, S., 2018. Baicalein suppress EMT of breast cancer by mediating tumor-associated macrophages polarization. *American journal of cancer research*, 8 (8), 1528–1540.
- Zhou, F., Zhuang, M. and Wu, Y., 2024. Mechanism of regulation of miR-433-3p/SRC by baicalin combined with oxaliplatin on proliferation and invasion of gastric cancer cells. *Drug Evaluation Research*, 47 (3), 529–537.
- Zhou, X. and Agazie, Y. M., 2012. The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR. *Cellular Signalling*, 24 (1), 140–150.